On May 28, 2024, Arbutus Biopharma Corporation announced that it held its 2024 annual general and special meetings of shareholders on May 22, 2024, and declared voting results. The Company stated that at the meeting, the Company?s shareholders, upon the recommendation of the Company?s Board of Directors, approved an amendment (the Plan Amendment) to the Company?s 2016 Omnibus Share and Incentive Plan, as supplemented and amended (the ?2016 Plan?), to (a) increase the aggregate number of common shares authorized for issuance under the 2016 Plan by 9,500,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted under the 2016 Plan by 9,500,000 common shares. Summaries of the 2016 Plan and the Plan Amendment are set forth in the Company?s Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities and Exchange Commission on April 10, 2024 (the ?Proxy Statement/Circular?).